Advertisement

Is Cervix Cancer a Disappearing Disease? Impact of HPV Vaccination in Developed Countries

  • Karen Canfell
  • Julietta Patnick
Chapter

Abstract

Human papillomavirus (HPV) vaccination of preadolescent girls has been found to be both effective and cost-effective and has now been introduced in many developed countries. Because rates of cervical cancer peak in older women, vaccination is expected to take some years to substantially reduce the overall rates of invasive cervical cancer, but in countries with high rates of vaccination coverage, cancer rates in younger women are expected to drop more rapidly. In countries that continue to screen women starting in their early twenties, rates of high-grade cervical intraepithelial neoplasia (CIN) should be reduced within a few years. Because of an expected reduction in women requiring treatment for CIN, HPV vaccination has the potential to reduce rates of preterm delivery, premature rupture of the membranes, and low birth weight in some settings, although the evidence on the association between treatment for CIN and obstetric complications is somewhat conflicting. In general terms, the timing and extent of the impact of vaccination on organized screening programs will depend on factors specific to each country, including coverage rates achieved in vaccination programs, the age range of catch-up vaccination, and the age of starting cervical screening. Cervical screening will need to continue for the foreseeable future since older cohorts are not vaccinated. Preliminary findings suggest that some form of cervical screening will continue to be cost-effective even in cohorts that are now being vaccinated as preadolescents. However, optimizing screening in the long term is likely to depend on an eventual transition to primary HPV screening at intervals of 5–6 years or even longer.

Keywords

Cervical Cancer Cervical Intraepithelial Neoplasia Invasive Cervical Cancer Cervical Screening Organize Screening Program 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Disclosure

KC declares that she is co-PI of a new trial of primary HPV screening in Australia (‘Compass’) which has received a funding contribution from Roche Molecular Systems, CA, USA.

References

  1. 1.
    de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13(6):607–15.PubMedCrossRefGoogle Scholar
  2. 2.
    Paavonen J, Naud P, Salmeron J, Wheeler C, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301–14.PubMedCrossRefGoogle Scholar
  3. 3.
    Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915–27.CrossRefGoogle Scholar
  4. 4.
    Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007;298(7):743–53.PubMedCrossRefGoogle Scholar
  5. 5.
    Canfell K, Chesson H, Kulasingam SL, Berkhof J, Diaz M, Kim JJ. Modeling preventative strategies against HPV-related disease in developed countries. Vaccine. 2012;30 Suppl 5:F157–67.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among children aged 19–35 months – United States, 2010. MMWR Morb Mortal Wkly. 2011;60(34):1157–63.Google Scholar
  7. 7.
    Health Protection Agency Immunisation Section. Annual HPV vaccine coverage in England in 2009/2010. Available at: http://immunisation.dh.gov.uk. Accessed Dec 2012.
  8. 8.
    Gertig DM, Brotherton JM, Saville M. Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. Sex Health. 2011;8(2):171–8.PubMedCrossRefGoogle Scholar
  9. 9.
    International Agency for Research on Cancer. IARC handbooks of cancer prevention volume 10: cervix cancer screening. Lyon: IARC Press; 2005.Google Scholar
  10. 10.
    Kitchener HC, Gilham C, Sargent A, Bailey A, Albrow R, Roberts C, et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer. 2011;47(6):864–71.PubMedCrossRefGoogle Scholar
  11. 11.
    Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla PP, Del MA, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11(3):249–57.PubMedCrossRefGoogle Scholar
  12. 12.
    Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357(16):1579–88.PubMedCrossRefGoogle Scholar
  13. 13.
    Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012;13(1):78–88.PubMedCrossRefGoogle Scholar
  14. 14.
    Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst. 2009;101(2):88–99.PubMedCrossRefGoogle Scholar
  15. 15.
    GAVI injects new life into HPV vaccine rollout The Lancet. 2013;381(9879): p. 1688.Google Scholar
  16. 16.
    Peres J. For cancers caused by HPV, two vaccines were just the beginning. J Natl Cancer Inst. 2011;103(5):360–2.PubMedCrossRefGoogle Scholar
  17. 17.
    Patel A, Galaal K, Burnley C, Faulkner K, Martin-Hirsch P, Bland MJ, et al. Cervical cancer incidence in young women: a historical and geographic controlled UK regional population study. Br J Cancer. 2012;106(11):1753–9.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Sasieni P, Castanon A, Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ. 2009;339:b2968.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Lancucki L, Sasieni P, Patnick J, Day TJ, Vessey MP. The impact of Jade Goody’s diagnosis and death on the NHS Cervical Screening Programme. J Med Screen. 2012;19(2):89–93.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Cuzick J, Castanon A, Sasieni P. Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20–29 in the UK. Br J Cancer. 2010;102(5):933–9.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet. 2011;377(9783):2085–92.PubMedCrossRefGoogle Scholar
  22. 22.
    Sasieni P, Castenon A, Cuzick J. The impact of cervical screening on young women: a critical review of the literature 2002–2009, NHSCSP publication no 31. Sheffield: NHS Cancer Screening Programmes; 2010.Google Scholar
  23. 23.
    Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet. 2006;367(9509):489–98.PubMedCrossRefGoogle Scholar
  24. 24.
    Arbyn M, Kyrgiou M, Simoens C, Raifu AO, Koliopoulos G, Martin-Hirsch P, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ. 2008;337:a1284.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Castanon A, Brocklehurst P, Evans H, Peebles D, Singh N, Walker P, et al. Risk of preterm birth after treatment for cervical intraepithelial neoplasia among women attending colposcopy in England: retrospective-prospective cohort study. BMJ. 2012;345:e5174.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE. The cost-effectiveness of male HPV vaccination in the United States. Vaccine. 2011;29(46):8443–50.PubMedCrossRefGoogle Scholar
  27. 27.
    Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol. 2008;111(1):167–77.PubMedCrossRefGoogle Scholar
  28. 28.
    NHS Cervical Screening Programme. Cervical screening programme, England. Annual review 2012. Sheffield: NHS Cervical Screening Programme; 2012.Google Scholar
  29. 29.
    Medical Services Advisory Committee. Automation assisted and liquid based cytology for cervical cancer screening. MSAC reference 1122, assessment report. Canberra: Department of Health and Ageing Australia; 2009.Google Scholar
  30. 30.
    Canfell K. Models of cervical screening in the era of human papillomavirus vaccination. Sex Health. 2010;7(3):359–67.PubMedCrossRefGoogle Scholar
  31. 31.
    Kitchener HC, Blanks R, Cubie H, Desai M, Dunn G, Legood R, et al. MAVARIC – a comparison of automation-assisted and manual cervical screening: a randomised controlled trial. Health Technol Assess. 2011;15(3).Google Scholar
  32. 32.
    Coupe VM, de Melker HE, Snijders PJ, Meijer CJ, Berkhof J. How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands. Vaccine. 2009;27(37):5111–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst. 2008;100(5):308–20.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Schiffman M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer. 2007;111(3):145–53.PubMedCrossRefGoogle Scholar
  35. 35.
    Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119(5):1095–101.PubMedCrossRefGoogle Scholar
  36. 36.
    Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337:a1754.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Schiffman M, Glass AG, Wentzensen N, Rush BB, Castle PE, Scott DR, et al. A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev. 2011;20(7):1398–409. doi:  10.1158/1055-9965. Epub 2011 May 20. Erratum in: Cancer Epidemiol Biomarkers Prev. 2012;21(8):1390–1
  38. 38.
    Australian Institute of Health and Welfare. Cervical screening in Australia 2007–2008: data report. Report no. CAN 50. Canberra: Department of Health and Ageing Australia; 2010.Google Scholar
  39. 39.
    Castellsague X, Diaz M, de Sanjose S, Munoz N, Herrero R, Franceschi S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006;98(5):303–15.PubMedCrossRefGoogle Scholar
  40. 40.
    Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995;87(11):796–802.PubMedCrossRefGoogle Scholar
  41. 41.
    Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62(3):147–72.PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Canfell K. Monitoring HPV, vaccination programmes. BMJ. 2010;340:c1666.PubMedCrossRefGoogle Scholar
  43. 43.
    Chaturvedi AK, Katki HA, Hildesheim A, Rodriguez AC, Quint W, Schiffman M, et al. Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. J Infect Dis. 2011;203(7):910–20.PubMedCentralPubMedCrossRefGoogle Scholar
  44. 44.
    Stanley M. Potential mechanisms for HPV vaccine-induced long-term protection. Gynecol Oncol. 2010;118(1 Suppl):S2–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007;25(26):4931–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Lancucki L, Fender M, Koukari A, Lynge E, Mai V, Mancini E, et al. A fall-off in cervical screening coverage of younger women in developed countries. J Med Screen. 2010;17(2):91–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  1. 1.Cancer Modelling Group, Adult Cancer Program, Prince of Wales Clinical School Level 4, Lowy Cancer Research CentreThe University of New South WalesSydneyAustralia
  2. 2.NHS Cancer Screening ProgrammesSheffieldUK

Personalised recommendations